CONCLUSIONS
In our study, the presence of ADAb and low trough levels seem to not
affect the therapeutic response in patients on TNF alpha antagonists.
Other tracks more than immunogenicity should be investigated to explain
the loss of response to these biotherapies.
Research funding: Immuno-Rheumatology research laboratory and Ministry
of health of Tunisia
Conflict of interest: None
Informed consent: Informed consent was obtained from all individuals
included in the study
Ethical approval: This study complies with the Declaration of Helsinki.
An ethical approval vas obtained from our local ethics committee
References:
- Vincent FB, Morand EF, Murphy K, Mackay F, Mariette X, Marcelli C.
Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific
neutralising agents in chronic inflammatory diseases: a real issue, a
clinical perspective. Ann Rheum Dis. 2013;72:165‑78.
- Stas P, Lasters I. Immunogenicity of therapeutic antibodies. Med Sci.
2009;25:1070‑7.
- van Schouwenburg PA, van de Stadt LA, De Jong RN, van Buren EE,
Kruithof S, De Groot E, et al. Adalimumab elicits a restricted
anti-idiotypic antibody response in autoimmune patients resulting in
functional neutralisation. Ann Rheum Dis. 2013;72:104‑9.
- Sethu S, Govindappa K, Alhaidari M, Pirmohamed M, Park K, Sathish J.
Immunogenicity to biologics: mechanisms, prediction and reduction.
Arch Immunol Ther Exp (Warsz). 2012;60:331‑44.
- Garcês S, Demengeot J, Benito-Garcia E. The immunogenicity of anti-TNF
therapy in immune-mediated inflammatory diseases: a systematic review
of the literature with a meta-analysis. Ann Rheum Dis.
2013;72:1947‑55.
- Tamas MM, Felea I, Rednic S. How much difference does the age at onset
make in early arthritis patients? Comparison between the ACR 1987 and
the ACR/EULAR 2010 classification criteria for rheumatoid arthritis at
the time of diagnosis. Rheumatol Int. 2013;33:2881‑4.
- Braun J, Van den Berg R, Baraliakos X, Boehm H, Burgos-Vargas R,
Collantes-Estevez E, et al. 2011 Update of the ASAS/EULAR
recommendations for the management of ankylosing spondylitis (AS). Ann
Rheum Dis. 2010;70:896-904.
- Satsangi J, Silverberg MS, Vermeire S, Colombel JF. The Monreal
classification of inflammatory bowel disease: controversies,
consensus, and implications. Gut. 2006;55(6):749-53.
- Prevoo ML, van ’t Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB,
van Riel PL. Modified disease activity scores that include
twenty-eight-joint counts. Development and validation in a prospective
longitudinal study of patients with rheumatoid arthritis. Arthritis
Rheum. 1995;38:44-8.
- Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A.
A new approach to defining disease status in ankylosing spondylitis:
the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol.
1994;21:2286‑91.
- Lukas C, Landewe R, Sieper J, Dougados M, Davis J, Braun J, et al.
Development of an ASAS-endorsed disease activity score (ASDAS) in
patients with ankylosing spondylitis. Ann Rheum Dis. 2008;68:18‑24.
- Best WR. Predicting the Crohn’s disease activity index from the
Harvey-Bradshaw Index. Inflamm Bowel Dis. 2006;12(4):304-10.
- Hock BD, Stamp LK, Hayman MW, Keating PE, Helms ET, Barclay ML.
Development of an ELISA-Based Competitive Binding Assay for the
Analysis of Drug Concentration and Antidrug Antibody Levels in
Patients Receiving Adalimumab or Infliximab. Ther Drug Monit.
2016;38:32‑41.
- Wolbink GJ, Aarden LA, Dijkmans BA. Dealing with immunogenicity of
biologicals: assessment and clinical relevance. Curr Opin Rheumatol.
2009;21:211‑5.
- Wadhwa M, Knezevic I, Kang HN, Thorpe R. Immunogenicity assessment of
biotherapeutic products: An overview of assays and their utility.
Biologicals. 2015;43:298‑306.
- Komaki Y, Komaki F, Sakuraba A, Cohen R. Approach to Optimize
Anti-TNF-α Therapy in Patients With IBD. Curr Treat Options
Gastroenterol. 2016;14:83-90.
- Mahmoud I, Rouached L, Ben Tekaya A, Saidane O, Bouden S, Jradi S, et
al. Immunogenicity of tumor necrosis factor therapy in patients with
spondyloarthritis. Drug Metabol Pers Ther. 2020-0139.
- Schellekens H. Immunogenicity of therapeutic proteins: clinical
implications and future prospects. Clin Ther. 2002;24:1720‑40.
- Mohanan D, Slütter B, Henriksen-Lacey M, Jiskoot W, Bouwstra JA,
Perrie Y, et al. Administration routes affect the quality of immune
responses: A cross-sectional evaluation of particulate
antigen-delivery systems. J Control Release. 2010;147:342‑9.
- Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, Macfarlane JD,
et al. Therapeutic efficacy of multiple intravenous infusions of
anti-tumor necrosis factor alpha monoclonal antibody combined with
low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum.
1998;41:1552‑63.
- Plasencia C, Pascual-Salcedo D, Nuño L, Bonilla G, Villalba A,
Peiteado D, et al. Influence of immunogenicity on the efficacy of
longterm treatment of spondyloarthritis with infliximab. Ann Rheum
Dis. 2012;71:1955‑60.
- Krieckaert CL, Bartelds GM, Lems WF, Wolbink GJ. The effect of
immunomodulators on the immunogenicity of TNF-blocking therapeutic
monoclonal antibodies: a review. Arthritis Res Ther. 2010;12:217.
- Arstikyte I, Kapleryte G, Butrimiene I, Venalis A. Influence of
Immunogenicity on the Efficacy of Long-Term Treatment with TNF α
Blockers in Rheumatoid Arthritis and Spondyloarthritis Patients.
Biomed Res Int. 2015;15:10.
- Pascual-Salcedo D, Plasencia C, Ramiro S, Nuño L, Bonilla G, Nagore D,
et al. Influence of immunogenicity on the efficacy of long-term
treatment with infliximab in rheumatoid arthritis. Rheumatol Oxf Engl.
2011;50:1445‑52.
- De Vries MK, Wolbink GJ, Stapel SO, de Vrieze H, van Denderen JC,
Dijkmans BA, et al. Decreased clinical response to infliximab in
ankylosing spondylitis is correlated with anti-infliximab formation.
Ann Rheum Dis. 2007;66:1252‑4.
- Kneepkens EL, Wei JC, Nurmohamed MT, Yeo KJ, Chen CY, van der
Horst-Bruinsma IE, et al. Immunogenicity, adalimumab levels and
clinical response in ankylosing spondylitis patients during 24 weeks
of follow-up. Ann Rheum Dis. 2015;74:396‑401.
- Ducourau E, Mulleman D, Paintaud G, Miow Lin DC, Lauféron F, Ternant
D, et al. Antibodies toward infliximab are associated with low
infliximab concentration at treatment initiation and poor infliximab
maintenance in rheumatic diseases. Arthritis Res Ther. 2011;13:105.
- Krintel SB, Grunert VP, Hetland ML, Johansen JS, Rothfuss M, Palermo
G, et al. The frequency of anti-infliximab antibodies in patients with
rheumatoid arthritis treated in routine care and the associations with
adverse drug reactions and treatment failure. Rheumatol Oxf Engl.
2013;52:1245‑53.
- Arends S, Lebbink HR, Spoorenberg A, Bungener LB, Roozendaal C, van
der Veer E, et al. The formation of autoantibodies and antibodies to
TNF-α blocking agents in relation to clinical response in patients
with ankylosing spondylitis. Clin Exp Rheumatol. 2010;28:661‑8.
- Hoxha A, Calligaro A, Tonello M, Ramonda R, Carletto A, Paolazzi G, et
al. The clinical relevance of early anti-adalimumab antibodies
detection in rheumatoid arthritis, ankylosing spondylitis and
psoriatic arthritis: A prospective multicentre study. Jt Bone Spine
Rev Rhum. 2016;83:167‑71.
- Vande Casteele N, Ferrante M, Van Assche G, Ballet V, Compernolle G,
Van Steen K, et al. Trough concentrations of infliximab guide dosing
for patients with inflammatory bowel disease. Gastroenterology.
2015;148:1320‑9.
- Pallagi-Kunstár É, Farkas K, Szepes Z, Nagy F, Szűcs M, Kui R, et al.
Utility of serum TNF-α, infliximab trough level, and antibody titers
in inflammatory bowel disease. World J Gastroenterol. 2014;20:5031‑5.
- Senabre Gallego JM, Rosas J, Macro-Mingo M, Garcia Gomez JA,
Santos-Soler G, et al. Clinical relevance of monitoring serum
adalimumab levels in axial spondyloarthritis. Rheumatol Int.
2019;39:841-9.
- Paramarta JE, Baeten DL. Adalimumab serum levels and antidrug
antibodies towards adalimumab in peripheral spondyloarthritis: no
association with clinical response to treatment or with disease
relapse upon treatment discontinuation. Arthritis Res Ther.
2014;16:160.
- Cludts I, Spinelli FR, Morello F, Hockley J, Valesini G, Wadhwa M.
Anti-therapeutic antibodies and their clinical impact in patients
treated with the TNF antagonist adalimumab. Cytokine. 2018;101:70‑7.
- Bandrés
Ciga
S, Salvatierra
J, López-Sidro
M, García-Sánchez
A, Durán
R, Vives
F, et al. An examination of the mechanisms involved in secondary
clinical failure to adalimumab or etanercept in inflammatory
arthropathies. J
Clin Rheumatol. 2015;21:115-9.
- Kuang B, King L, Wang HF. Therapeutic monoclonal antibody
concentration monitoring: free or total? Bioanalysis. 2010;2:1125‑40.
- O’Meara S, Nanda KS, Moss AC. Antibodies to infliximab and risk of
infusion reactions in patients with inflammatory bowel disease: a
systematic review and meta-analysis. Inflamm Bowel Dis. 2014;20:1-6
- Vande Casteele N, Gils A, Singh S, Ohrmund L, Hauenstein S, Rutgeerts
P, et al. Antibody response to infliximab and its impact on
pharmacokinetics can be transient. Am J Gastroenterol.
2013;108:962‑71.
Table 1: Patients and disease characteristics at baseline